Efficacy and safety of intravitreal ranibizumab alone and combined laser therapy for the treatment of DME: a meta-analysis

Authors: Ji Dongxiao,  Jin Yinghui,  Ren Xiangying,  Li Xuhui,  Huang Qiao,  Hu Xin,  Zhao Bo,  Jin Haiying
DOI: 10.3760/cma.j.cn115989-20220622-00291
Published 2023-10-10
Cite as Chin J Exp Ophthalmol, 2023, 41(10): 1004-1010.

Abstract                            【Download PDF】 【Read Full Text

Objective

To evaluate the efficacy and safety of intravitreal ranibizumab combined with laser (IVR+ Laser) and the intravitreal ranibizumab (IVR) monotherapy for the treatment of diabetic macular edema (DME).

Methods

A meta-analysis was conducted on randomized controlled trial (RCT) literature related to IVR+ Laser therapy and IVR alone for DME.Databases including Cochrane Library, PubMed, EMbase, Web of Science, SinoMed, CNKI, VIP and WanFang Data were searched from their inception to April 2022.Literature screening, data extraction, quality evaluation and cross-checking were conducted independently by two researchers according to inclusion and exclusion criteria.Then a meta-analysis was conducted using RevMan 5.4.1 software.The two therapies were compared in terms of best corrected visual acuity (BCVA), central macular thickness (CMT), mean number of injections and adverse events.

Results

Twelve RCTs involving 1 695 eyes were included in the study.Meta-analysis showed that at the end of follow-up, IVR+ Laser demonstrated better improvement in BCVA and CMT than IVR alone, and there were significant differences in the changes in BCVA and CMT between the two groups (weighted mean difference[WMD]=-0.66, 95% confidence interval[CI]: -1.11–0.21, P<0.01; WMD=-5.05, 95%CI: -9.21–0.89, P=0.02).IVR+ Laser required significantly fewer injections than IVR alone (WMD=-1.16, 95%CI: -2.07–0.25, P=0.01).There were no significant differences in the adverse events incidence between the two therapies (all at P>0.05).

Conclusions

The safety of IVR+ Laser is comparable to IVR alone, and it requires fewer injections for the treatment of DME.

Key words:

Macular edema; Diabetes complications; Ranibizumab; Laser therapy; Vascular endothelial growth factors; Light coagulation; Meta-analysis

Contributor Information

Ji Dongxiao

Department of Ophthalmology, Huaihe Hospital of Henan University, Kaifeng 475000, China

Jin Yinghui

Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, China

Ren Xiangying

Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, China

Li Xuhui

Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, China

Huang Qiao

Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, China

Hu Xin

Department of Ophthalmology, Huaihe Hospital of Henan University, Kaifeng 475000, China

Zhao Bo

Department of Ophthalmology, Huaihe Hospital of Henan University, Kaifeng 475000, China

Jin Haiying

Department of Ophthalmology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200040, China

(Read 44 times, 1 visits today)